Danilo Casimiro joined Aeras as its the Chief Scientific Officer (CSO) in February 2016. Dr. Casimiro oversees all preclinical activities, including vaccine discovery, pre-clinical development, and quality assurance, and shares executive responsibility for the organization with the CEO and CMO.
Prior to joining Aeras, he was Executive Director in the Department of Infectious Diseases and Vaccine Research at Merck & Co. He has 20 years of experience in research and development at Merck, where he was responsible for several vaccine and biologics discovery programs in the infectious disease and oncology areas. He contributed to the development and licensure of Merck’s human papillomavirus vaccines, and the selection of numerous vaccine candidates (including Merck’s current cytomegalovirus, Ebola, and dengue vaccine development candidates) and monoclonal antibodies for clinical development. He also served on numerous advisory committees to the BMGF Global Health Program, IAVI, HIV Vaccine Enterprise, NIH IPCAVD, Human Vaccine Project, and the USAID. Dr. Casimiro currently holds over 20 patents on vaccine candidates and technologies, and has co-authored more than 100 scientific articles in biological and biomedical research. He received his B.S. degree in Chemistry from the University of the Philippines and his Ph.D. degree in Chemistry from the California Institute of Technology.